Patient Support Program Highlights^1,2,3

• Rejection is the major barrier to successful transplantation¹
• Progress in our understanding of the immunobiology of rejection has been translated to the development of immunosuppressive agents²
• Modern immunopharmacological interventions have contributed to the clinical success observed following transplantation²
• In solid organ transplantation the induction of immunosuppression in the early phase is required to²
  • Prevent graft rejection
  • Improve graft and patient survival
  • Improve overall patient quality of life

>90% graft survival one-year post transplantation with immunosuppressant

With the immunosuppressive drugs, one-year graft survival now exceeds 90% in most centres³

We at Viatris support needy patients to get the Tacrolimus and Everolimus level testing to maintain healthy graft and intern improve QOL.